We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVSN
RNS Number : 7890T
Verseon Corporation
06 July 2018
July 6, 2018
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 17,009 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance"). The Issuance is in connection with the Verseon Corporation 2015 Equity Incentive Plan and pursuant to the regularly scheduled vesting of previously granted restricted stock units and is to correct a discrepancy in regards to an admission previously announced on 31 October 2016.
The 17,009 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on July 10, 2018 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,618,042 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,575,125. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Verseon Corporation www.verseon.com Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000 Cenkos Securities (NOMAD and Joint Broker) +44 (0) 20 7397 Neil McDonald / Beth McKiernan 8900 Cantor Fitzgerald Europe (Joint Broker) +44 (0) 20 7894 Marc Milmo / Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) +44 (0) 20 7466 Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts +44 (0) 1737 821 Simon Vane Percy 890
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEAPXSELFPEFF
(END) Dow Jones Newswires
July 06, 2018 02:00 ET (06:00 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions